The Impact of Fracture Liaison Services on Outcomes in Older Patients: A Systematic Review
Abstract
Osteoporotic fractures are fractures caused by underlying osteoporosis that occur after minimal trauma. They represent a prevalent public health problem worldwide with significant economic burden and negative effects on quality of life. Fracture liaison services (FLS) are multidisciplinary programs aimed to decrease secondary fractures in high-risk patients by improving the post-fracture care gap. This review analyzes the impact of FLS on patient outcomes, especially refracture risk and osteoporosis medication initiation. This review was conducted using Ovid (MEDLINE), CINAHL, and Web of Science. Randomized controlled trials (RCTs), cross-sectional studies, observational studies, longitudinal studies, and cohort prospective/retrospective studies published between 2010 and 2024 were included. Selected articles also had a focus on refracture risk and/or osteoporotic medication initiation, a patient cohort mean age greater than 65 years old, and patients presenting with an initial osteoporotic fracture (as opposed to a history of fractures). Out of 727 total articles screened, 49 were included. The most prescribed medications were zoledronic acid, denosumab, and alendronate. FLS implementation was generally associated with a decrease in refracture rate, but only 11 out of 20 studies that assessed this found a statistically significant difference. Variability in refracture rates among studies may be due to differences in program intensity and patient demographics (namely, age…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s Pacemaker
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin
- Cancer epigenetics: Moving forward
- Current developments in LC-MS for pharmaceutical analysis
- Myricetin: A comprehensive review on its biological potentials
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.